Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Lenalidomide is an effective therapeutic agent for chronic lymphocytic leukemia (CLL).
• Understanding predictive biomarkers for lenalidomide treatment is crucial for patient stratification.

Purpose of the Study:

• To identify gene expression profiles associated with lenalidomide response in CLL patients.
• To investigate the role of SHISA3 in lenalidomide sensitivity and Wnt signaling in CLL.

Main Methods:

• Phase II clinical trial involving 27 CLL patients treated with lenalidomide.
• Immune cell subset analysis (T lymphocytes, NK, monocytes, dendritic cells) at baseline and post-treatment.
• Gene expression analysis of pre-treatment leukemic cells from 16 CLL patients.

Main Results:

• No significant differences in immune cell levels or cytokines between responders (R) and non-responders (NR).
• CLL patients sensitive to lenalidomide exhibited a distinct gene expression profile.
• SHISA homolog 3 (SHISA3) was the most significantly upregulated gene in responders (fold change +23 vs. NR).
• SHISA3-high CLL cases showed restrained Wnt signaling activation and increased sensitivity to lenalidomide-induced apoptosis.

Conclusions:

• SHISA3 is a potential predictive biomarker for identifying CLL patients who will benefit from lenalidomide monotherapy.
• SHISA3 expression levels correlate with lenalidomide sensitivity and apoptosis induction in CLL.